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PRimary Care Opioid Use Disorders
treatment (PROUD) trial protocol: a pragmatic,
cluster‑randomized implementation trial
in primary care for opioid use disorder
treatment
Cynthia I. Campbell1* , Andrew J. Saxon2, Denise M. Boudreau3, Paige D. Wartko3, Jennifer F. Bobb3,
Amy K. Lee3, Abigail G. Matthews4, Jennifer McCormack4, David S. Liu17, Megan Addis3, Andrea Altschuler1,
Jeffrey H. Samet5, Colleen T. LaBelle5, Julia Arnsten6, Ryan M. Caldeiro7, Douglas T. Borst8, Angela L. Stotts9,
Jordan M. Braciszewski10, José Szapocznik11, Gavin Bart12, Robert P. Schwartz13, Jennifer McNeely14,
Jane M. Liebschutz15, Judith I. Tsui16, Joseph O. Merrill16, Joseph E. Glass3, Gwen T. Lapham3, Sean M. Murphy18,
Zoe M. Weinstein19, Bobbi Jo H. Yarborough20 and Katharine A. Bradley3

Abstract
Background: Most people with opioid use disorder (OUD) never receive treatment. Medication treatment of OUD
in primary care is recommended as an approach to increase access to care. The PRimary Care Opioid Use Disorders
treatment (PROUD) trial tests whether implementation of a collaborative care model (Massachusetts Model) using a
nurse care manager (NCM) to support medication treatment of OUD in primary care increases OUD treatment and
improves outcomes. Specifically, it tests whether implementation of collaborative care, compared to usual primary
care, increases the number of days of medication for OUD (implementation objective) and reduces acute health care
utilization (effectiveness objective). The protocol for the PROUD trial is presented here.
Methods: PROUD is a hybrid type III cluster-randomized implementation trial in six health care systems. The intervention consists of three implementation strategies: salary for a full-time NCM, training and technical assistance for
the NCM, and requiring that three primary care providers have DEA waivers to prescribe buprenorphine. Within each
health system, two primary care clinics are randomized: one to the intervention and one to Usual Primary Care. The
sample includes all patients age 16–90 who visited the randomized primary care clinics from 3 years before to 2 years
after randomization (anticipated to be > 170,000). Quantitative data are derived from existing health system administrative data, electronic medical records, and/or health insurance claims (“electronic health records,” [EHRs]). Anonymous staff surveys, stakeholder debriefs, and observations from site visits, trainings and technical assistance provide
qualitative data to assess barriers and facilitators to implementation. The outcome for the implementation objective
(primary outcome) is a clinic-level measure of the number of patient days of medication treatment of OUD over the
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2 years post-randomization. The patient-level outcome for the effectiveness objective (secondary outcome) is days of
acute care utilization [e.g. urgent care, emergency department (ED) and/or hospitalizations] over 2 years post-randomization among patients with documented OUD prior to randomization.
Discussion: The PROUD trial provides information for clinical leaders and policy makers regarding potential benefits
for patients and health systems of a collaborative care model for management of OUD in primary care, tested in realworld diverse primary care settings.
Trial registration # NCT03407638 (February 28, 2018); CTN-0074 https://clinicaltrials.gov/ct2/show/NCT0340763
8?term=CTN-0074&draw=2&rank=1
Keywords: Medication, Buprenorphine, Opioid use disorder, Primary care, Nurse care manager, Collaborative care,
Pragmatic trial

Introduction
Of the more than 2 million individuals in the United
States with opioid use disorder (OUD), the vast majority
do not receive treatment [1, 2]. Increasing treatment of
OUD is critical, but not likely to be achieved unless it is
provided in general medical settings in addition to specialty substance use treatment clinics [1, 3]. Buprenorphine and naltrexone are two FDA-approved medications
with demonstrated efficacy for OUD, which can be provided in primary care (PC) settings [4, 5]. Although the
use of medication treatment for OUD has increased over
time, it reaches only 51% of privately insured patients
with OUD [6], and merely 25% of Medicaid patients with
OUD [7]. Most patients with OUD do not receive OUD
treatment in PC [8, 9].
Substantial barriers to treating OUD in PC persist
[10–14]. These include perceptions that treating OUD
is out of the scope of PC practice, which lacks the time,
resources, structure, and behavioral interventions
required for OUD treatment [15]. Concerns are sometimes raised that PC cannot provide high quality OUD
treatment [15]. Finally, many experts believe that pessimism and stigma pose major, if often unspoken, barriers
[12]. Clinicians express concern that patients with OUD
are difficult and could overwhelm PC practices [15].
Effective strategies exist to successfully implement
high quality care for treating OUD in medical settings.
A recent review identified 6 models of OUD treatment
in PC [16]. Successful models generally relied on teambased approaches to address the above barriers. One
of the models with the most support in the literature is
the Massachusetts Collaborative Care Model [17–19].
The Massachusetts model (hereafter the “MA Model”)
includes a full time OUD nurse care manager (NCM) as
part of a team-based approach that shares care between
the NCM and PC provider, with the nurse providing
assessment, education, rapid access to medication, monitoring, and care coordination.
The MA Model has demonstrated effectiveness engaging and maintaining PC patients in OUD treatment, as

well as attracting new patients into PC for OUD treatment [17, 18]. The model has been associated with high
rates of persistent treatment at 12 months (51–67%) [17],
and it is being tested in the recently funded and congressionally-mandated HEALing Communities multisite trial [20]. However, the MA Model has been used
predominantly in publicly-financed Federally Qualified
Health Centers (FQHCs) in MA [17, 18, 21] and is not
widely implemented outside MA. As implemented in
FQHCs in MA [19], each NCM was expected to care for
a panel of approximately 100 patients with OUD after
full implementation, suggesting that the model could be
cost-effective [18]. However, to date, other health systems
have not made the upfront investment of hiring a fulltime NCM, as required by the MA Model. This highlights
the need for evidence of the MA Model’s feasibility, effectiveness and costs in other regions and across diverse
health systems.
The PRimary care Opioid Use Disorder (PROUD)
trial is testing whether implementing the MA Model
in PC across six diverse health systems and regions can
increase OUD medication treatment and secondarily
improve outcomes of patients with OUD. The purpose of
this report is to describe the PROUD protocol.

Methods
Objectives and hypotheses

The PROUD trial is a pragmatic, hybrid type III clusterrandomized implementation trial [22], a design which
includes both a primary implementation objective and
a secondary effectiveness outcome. PROUD tests strategies for implementing the MA Model in primary care,
while secondarily evaluating the effectiveness of implementation for improving patient outcomes. The implementation objective (Objective 1; primary aim) is to test
whether the MA Model, as compared to Usual PC in six
diverse health systems, increases patient-days of medication treatment of OUD with either buprenorphine or
extended release injectable naltrexone (XR-NTX) in PC,
as documented in electronic medical records (EMRs)
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2 years post-randomization. The primary implementation hypothesis is that the number of patient days of
medication treatment of OUD is significantly greater in
clinics randomized to the PROUD intervention compared to clinics randomized to Usual PC.
The effectiveness objective (Objective 2, powered secondary aim) evaluates whether the MA Model decreases
acute care utilization in PC patients with OUD. The primary effectiveness hypothesis is that PC patients with
documented OUD in the 3 years prior to randomization who receive care in PROUD intervention clinics,
compared to those who receive care in Usual PC clinics,
have fewer days of acute care utilization (e.g., in urgent
care, emergency department [ED] and/or hospital) in
the 2 years after randomization. This effectiveness objective reflects whether the PROUD intervention decreases
acute health care utilization, a proxy for improved patient
health outcomes.
Other study objectives include: (1) evaluating whether
sex and race/ethnicity modify the impact of the PROUD
intervention; (2) testing whether the intervention
improves other implementation or effectiveness outcomes; and (3) identifying barriers and facilitators to
implementation of the MA Model. In addition, since findings from the developmental phase of PROUD (Phase 1,
described below) suggested that the recruited clinics may
not be typical, observational analyses compare recruited
clinics to other non-recruited (i.e. non-randomized)
Usual PC clinics in the same system at baseline. Finally,
four health systems in PROUD Phase 1 had unique care
models for OUD treatment that health system leaders
thought might be equal or superior to the MA Model.
Thus, observational analyses compare outcomes in the
PROUD intervention clinics to outcomes in these “exemplar” PC clinics.
Overview of trial design

The PROUD trial is being conducted in six health systems across the United States (Fig. 1). These health systems were recruited from among 11 health systems that
participated in Phase 1. For PROUD Phase 2—the trial
described in this report—each participating health system recruits two PC clinics willing to implement the
MA Model, resulting in a total of 12 clinics across the
six health systems. One of the two recruited PC clinics
in each health system is randomly assigned to implement
the MA Model, while the other is randomly assigned
to continue Usual PC. The PROUD Data and Analytics
Team obtains all quantitative data for sample identification and measures solely from existing electronic health
records (EHRs), which include but are not limited to electronic administrative data, patients’ EMRs, and/or electronic data on health insurance claims, during a baseline
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(pre-randomization) period and follow-up (post-randomization) period. The PROUD Implementation Monitoring Team obtains qualitative data via: anonymous staff
surveys at baseline and after the trial ends; stakeholder
debriefs throughout the trial; and observations at site
visits, trainings, and technical assistance (TA) throughout the trial. The PROUD trial leadership structure and
teams are depicted in Additional file 1: Appendix S1;
staff surveys and implementation monitoring tools are
provided in Additional file 2: Appendix S2, Additional
file 3: Appendix S3 and Additional file 4: Appendix S4.
An independent, commercial Institutional Review Board
(IRB) approved the study including providing waivers of
consent and HIPAA authorization; all sites ceded to it.
Conceptual framework

The PROUD Trial design is guided by the Practical, Robust Implementation and Sustainability Model
(PRISM) framework for implementation, [23] which
combines domains that impact the success of implementation. It includes four domains of barriers and facilitators to implementation: (1) the PROUD intervention,
and how it interacts with recipients of the intervention;
(2) the recipients of the intervention, including patient,
clinician, and organization; (3) the implementation and
sustainability infrastructure of the health system, including quality improvement teams, as well as space and
EMR; and (4) the external environment, including regulatory policies, healthcare financing, and national quality measures [23]. These domains guide qualitative data
collection by the PROUD Implementation Monitoring
Team (See Data Sources). The PRISM’s outcome domains
that reflect the success of implementation are contained
within the RE-AIM framework: Reach, Effectiveness,
Adoption, Implementation fidelity, and Maintenance of
the intervention [24–26]. The first four RE-AIM domains
guide selection of PROUD outcome measures.
Developmental phase: PROUD Phase 1

The Developmental Phase of PROUD (Phase 1) lasted
from January 2017 to November 2017. Objectives for
Phase 1 were to select health systems that could obtain
institutional support for the trial and demonstrate the
feasibility of data collection. Phase 1 included 11 health
systems from across the country that indicated they
could provide the required data and possibly obtain permissions for participation in the main trial. From January to March 2017, lead investigators in the 11 Phase 1
health systems (“Site PIs”) worked to engage their health
system leaders to assess whether the health system would
be willing to participate in the PROUD trial. Six of the
11 Phase 1 sites were able to obtain the required support
from all levels of their health systems within the required
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Fig. 1 Schematic of PROUD study

timeframe. Other activities during Phase 1 included
preparation for data collection (e.g., development of
measures and a data dictionary to create common data
fields from the EMR and insurance claims data across
the health systems) and obtaining approval of the NIDA
National Drug Abuse Treatment Clinical Trials Network Data and Safety Monitoring Board. As above, one

important finding of Phase 1 was that many clinics were
unable to participate due to lack of leadership or PC provider support; consequently observational analyses were
planned comparing recruited clinics to non-recruited
(i.e. non-randomized) clinics in the same system at baseline. Another important finding of Phase 1 was that four
health systems included PC clinics with unique models of
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OUD care (“exemplar” hereafter) that health system leaders felt were potentially as—or more—effective than the
MA Model tested in the PROUD trial. As a result, observational analyses were also added to compare outcomes
in the four exemplar clinics to outcomes in the six sites
randomized to the PROUD intervention (Phase 2).
Site selection for PROUD trial

Health systems were eligible for the PROUD trial based
on: (1) health system and clinic leaders providing letters
of support agreeing to participate in the trial, (2) having two adequately-sized PC clinics (i.e., approximately
10,000 unique patients with visits in a year) willing to participate by integrating a NCM into their clinic, (3) having at least three PC providers in the clinic willing to be
waivered to prescribe buprenorphine, (4) a demonstrated
ability to obtain the data necessary for the PROUD outcome measures—specifically days of treatment with
medication for OUD and acute care utilization, (5) ability to meet all data sharing and regulatory requirements,
(6) geographic, demographic and health system diversity,
and (7) clinics not in close proximity to reduce cross-over
potential. The six health systems selected included: two
integrated insurance and delivery systems (Henry Ford
Health System, MI; Kaiser Permanente [KP] Washington, WA), a community health system (Multicare Health
System, WA), two university affiliated safety-net health
systems (Harris Health System, TX; Montefiore Health
System, NY), and a university-affiliated health system
(University of Miami Health System, FL). For purposes
of the trial, a “clinic” could be a cluster of two to three
nearby smaller clinics that would function as a unit, sharing the NCM if randomized to the PROUD intervention.
Three of the 12 recruited clinics are a cluster of two clinics (hereafter referred to simply as “clinics”).
Phase 2: PROUD trial timeline

The PROUD trial includes three study periods: (1)
startup; (2) intervention period (24 months); and (3) final
data collection, analyses and dissemination (18 months).
• Startup period Start-up lasts from November 2017–
February 2018 and includes arranging contracts and
data use agreements with each health system, obtaining approval from a central IRB for all health systems,
and preparing for randomization.
• Intervention period The 2-year intervention period
(3/1/2018–2/29/2020) begins with randomization
on 2/28/2018. The intervention period includes an
estimated 6 months required to hire, onboard, and
train a NCM, leaving about 18 months remaining for
the NCM to support OUD treatment in the PROUD
intervention clinic. During this period the Data and
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Analytics Team extracts limited datasets from the
EMR and insurance claims data four times for reports
to the Data and Safety Monitoring Board (with health
systems deidentified) and refinement of data specifications and measures, while the Implementation
Monitoring Team conducts both formative evaluation and qualitative data collection (described below).
• Final data collection and analysis Final trial data
collection, cleaning, and analysis of the main and
secondary trial outcomes occur in the 18 months
(3/1/2020–8/31/2021) after the intervention period
ends.
Overview of the MA Model

The MA Model is a team-based, collaborative care
approach that uses a full-time clinic-based NCM to integrate medication treatment of OUD into PC [17, 18].
The model is one of shared care between the NCM and
the PC providers who prescribe OUD medications, in
which agreed upon protocols, per the MA Model Office
Based Addiction Treatment (OBAT) manual [27], allow
the NCM to provide much of the routine care, with the
provider’s role focused on diagnosis and treatment decisions, including referral to specialty addictions care
when appropriate. The role of the NCM includes connecting with health system departments, hospitals, and
community services so they can refer patients to PC for
OUD treatment; assessment and support and engagement of patients seeking OUD treatment; coordinating
with insurance plans; providing rapid access to intake
assessments; coordinating prescriber visits to diagnose
and prescribe buprenorphine or XR-NTX; support for
medication initiation; monitoring and coordinating prescriptions refills for stable patients; checking the state
Prescription Drug Monitoring Program; coordinating
with outside agencies monitoring treatment; and monitoring urine drug tests. Although each health system
chose how to use urine drug tests as part of care for
OUD, in general, urine drug tests were used at the initial
assessment of new patients and for monitoring during
treatment to help guide clinical care. In the MA model,
urine drug tests serve as a clinical tool in treating patients
with OUD, allowing the NCM to have a conversation
with patients and, when urine drug tests are positive or
unexpected, allows the NCM to offer more support (e.g.
increased frequency of visits), provide other tools or link
to additional services, or talk about fentanyl, a “critical lab value,” which patients may not know was in their
drug supply. The NCM role allows the PC provider to
treat OUD in the normal flow of PC and minimizes additional workload. The NCM becomes an expert in OUD
treatment and also plays an educational role to overcome
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barriers to OUD treatment both within the clinic and
in the larger health system, with a focus on decreasing
stigma by using non-stigmatizing language and normalizing OUD treatment in PC [17, 18, 28].
The PROUD trial intervention

The PROUD trial intervention consists of three strategies to implement the MA Model: (1) providing funding
and guidance to hire a NCM; (2) training and TA for the
NCMs; and (3) PC provider training and mentoring. Further details of the three strategies are provided in Table 1.
Formative evaluation [29] of implementation throughout the trial assesses whether barriers and/or facilitators
necessitate refinements to implementation strategies.
PROUD comparison condition: usual primary care

Clinics randomized to Usual PC do not receive any
resources or support from the study. Usual PC clinics are
free to improve OUD treatment in any way they choose,
but they are asked not to use the OBAT manual from
Boston Medical Center to replicate the PROUD intervention in the Usual PC clinic. Usual PC is selected as
the appropriate comparator because most PC clinics do
not currently offer or have programs to support OUD
treatment [16], but this could change as health systems
respond to the opioid crisis.
Primary care clinics used in observational comparisons
Non‑recruited PC clinics

In order to assess whether the recruited (randomized)
PROUD clinics differ from other PC clinics in the same
system, all health systems in the PROUD trial were asked
during Phase 1 if they could also provide the same EHR
data needed for the trial, for four additional non-recruited
PC clinics. Five health systems were able to provide such
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data; four eligible non-recruited PC clinics were selected
for each of those 5 systems (Fig. 1).
Exemplar PC clinics

There are four exemplar clinics, two in systems participating in the PROUD trial (Montefiore and KP Washington) and two from other health systems from Phase
1 (KP Northwest and KP Colorado). In Montefiore and
KP Washington, care for OUD had been implemented
into routine care in one or more PC clinic(s), at a distance from the PROUD intervention clinics, with all or
most PC providers prescribing buprenorphine; the largest in each system is chosen as the exemplar clinic. In KP
Northwest and KP Colorado, a specialty addiction treatment program with features designed to lower barriers to
OUD care, located in the same building or near a large
PC clinic, is selected as the exemplar PC clinic (Fig. 1).
Randomization

Randomization (1:1) is at the level of the PC clinic
(n = 12), stratified by health system. As a result, six clinics
(one clinic per health system) are assigned to the PROUD
Intervention condition and six clinics (one clinic per
health system) are assigned to the Usual PC condition.
Ethical considerations

Waivers of informed consent and HIPAA Authorization are obtained for this study consistent with the three
requirements of pre-2018 regulations (45 CFR 46.116(d)
(3) [31]. These are appropriate because: (1) health system
leaders and clinicians are implementing the MA Model in
their system as part of improvements in clinical care; (2)
risks are minimal when using secondary data with appropriate privacy safeguards, as in observational studies,
without any contact between research staff and patients;
and (3) the critically important questions about how to

Table 1 The PROUD intervention: three implementation strategies
(1) Providing funding and guidance to hire a NCM The PC clinic is provided funding for 1.0 Full Time Equivalent salary for a NCM for 2 years. The clinic leaders and health system then recruit, hire, and onboard a full-time NCM. Of note, although the PROUD trial provides financial support for the NCM salary
and support for training and TA for the NCMs, health system leaders, not researchers, implement the MA Model in the intervention clinic. Further, the
health system and its clinicians provide all clinical care to patients
(2) Training and ongoing technical assistance (TA) A TA team at Boston Medical Center provides training before the NCMs begin seeing patients and
subsequent, ongoing support. This TA support includes training, an OBAT manual [27], a weekly videoconference to support and coach PROUD NCMs,
and one-on-one consultation for questions as needed. The TA team’s OBAT nurses train the site NCMs in Boston for approximately 1.5–2 days. Training includes both didactic sessions and “shadowing” experienced NCMs while they provide care for patients with OUD. After each NCM is trained, a
member of the TA team makes an in-person site visit to that intervention clinic offering training to all PC staff and meeting with the team providing
PC OUD treatment. The weekly videoconferences consist of checking in with the NCMs about their patients, with a focus on problem-solving patient-,
clinic- and system-level challenges, didactics on common challenges, and modeling of non-stigmatizing language and patient-centered care. A
second site visit is optional to address challenges at the nursing level
(3) PC providers trained and mentored At least three PC providers are required to agree to prescribe buprenorphine, obtaining training and a Drug
Enforcement Administration (DEA) waiver if not already waivered. Each PC prescriber is also asked to identify a mentor who can either be a local
addictions expert in their health system or a mentor from a national program of voluntary mentors through the Providers Clinical Support System
[30]. The TA team facilitates engagement between buprenorphine prescribers and their mentors during the site visit(s)

Campbell et al. Addict Sci Clin Pract

(2021) 16:9

implement improved OUD treatment in PC could not
practicably be answered without such waivers because
recruiting patients and requiring provision of informed
consent would result in a biased sample, compromising scientific validity of the assessment of the clinic-level
intervention. A Data Safety Monitoring Board approved
the protocol. All protocol modifications are approved
by the IRB—and if important summarized on clinicaltrials.gov. The PROUD study has no interim stopping
guidelines.
Samples
PROUD trial

The PROUD sample includes PC patients age 16–90 years
old with at least 1 in-person visit to a participating PC
clinic (n = 12) from 3 years before to 2 years after randomization. The total sample of PC patients in the trial is
anticipated to be over 170,000 across the 12 clinics in the
six health systems. The main implementation objective
(primary outcome of days of OUD treatment) is assessed
in the full study sample of all PC patients with visits during the intervention period (from randomization to trial
end). The main effectiveness objective (days of acute care
utilization) is evaluated in the subsample of PC patients
who have documentation of an OUD diagnosis in their
EHR data up to 3 years prior to randomization.
Samples for observational analyses of non-recruited
Usual PC clinics and exemplar clinics parallel the main
trial sample inclusion criteria for implementation or
effectiveness outcomes.
Data sources and collection
Quantitative data sources available for all PC clinics
in the trial

All quantitative measures for randomized, non-recruited
Usual PC, and exemplar clinics are secondary data ascertained from EHRs—health system administrative databases, EMRs, and insurance claims—with insurance
claims only available from two sites that provide health
insurance for some of their patients. Data domains
include demographics, diagnoses, outpatient medication
orders for medications of interest [(OUD treatments,
naloxone, opioids, sedative hypnotics, stimulants, antidepressants, muscle relaxants, and medications to treat
human immunodeficiency virus (HIV), Hepatitis C virus
(HCV), alcohol use disorder (AUD), and neuropathy)],
pharmacy dispensing data (if available), procedures,
select laboratory tests including urine drug tests and
HCV and HIV related laboratory tests, health care utilization, and deaths documented in EHRs. Final data collection occurs 7 months after the end of the trial, allowing
6 months for the lag in insurance claims data (two health
systems). The Data Safety Monitoring Board reviews data
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collected, including safety data (e.g. overdose) approximately every 6 months. Data quality checks and information on data management, storage and security can be
obtained from the lead investigator. If the intervention
increases OUD treatment, funding for an ancillary study
of the impact on mortality will be sought, including data
from the National Death Index (NDI).
Data available only from PROUD intervention clinics

The NCM provides weekly counts of patients to the TA
team as part of ongoing weekly support, and these data
are also provided to the Implementation Monitoring
Team. Each week the NCM sends counts of the following: the number of new patients the NCM talked to about
treatment; the number of full OUD intake assessments;
the number of patients who newly started treatment,
were re-engaged, or who transferred OUD care to the
intervention clinic (i.e. had already started medication
treatment for OUD elsewhere); the number of scheduled
follow-up and walk-in patients seen; the number of XRNTX injections given; the number of no shows for scheduled NCM visits, and the number “discharged” (screened
but never started on medication, incarcerated, transferred to higher level of care, lost to follow-up, deceased,
or discharged due to administrative or medical reasons).
From these data, weekly summary counts of total number
of patients ever managed by the NCM and total number
of patients in treatment currently at each intervention
clinic are shared with Site PIs, the Implementation Monitoring Team, and trial leadership.
Anonymous PC staff survey

An anonymous survey of PC staff in PROUD intervention and Usual PC clinics is conducted at baseline and
after the end of the trial. This survey asks each staff member for their role and years in practice (generally and in
the clinic), and includes eight questions about the appropriateness of, feasibility of, and attitudes toward treating
OUD in their PC clinic (Appendix S3).
Qualitative data source: ongoing implementation
monitoring

An Implementation Monitoring Team holds weekly
meetings to identify barriers and facilitators to implementation across four domains: intervention; recipients
(patients, clinicians, staff, and leaders); healthcare infrastructure; and the external environment [23] to inform
any adaptations to the intervention strategies to enhance
implementation (i.e., formative evaluation) and collect
contextual data to support interpretation of trial results.
The Implementation Monitoring Team includes four
study team members from the lead investigative team,
including the lead investigator.
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Qualitative data from all PROUD clinics To understand
the full context of OUD care at each clinic (intervention
and control), the Site PI(s) and project manager at each of
the six health systems conduct formal interviews with key
informants in their health systems at baseline and then
every 6 months (Appendix S2; Appendix S4). These interviews cover four qualitative domains of the PRISM [23]
model—(1) the intervention itself, (2) recipients of the
intervention including the health system—organizational
characteristics, leaders, managers, staff and patients, (3),
implementation and sustainability infrastructure and (4)
external environment [23]. Once the site PI(s) and project manager in each health system have completed their
key informant interviews, the Implementation Monitoring Team debriefs the Site PI(s) and project manager on
what they learned from their interviews with regard to
potential barriers and facilitators to OUD treatment and
implementation, and monitor changes over time related
to the context of implementation and care for patients
with OUD in each health system. Parallel assessments of
OUD care and other contextual factors are also conducted
for exemplar clinics.
Qualitative data on intervention clinics only The Implementation Monitoring Team also collects qualitative
data specific to the intervention clinics to understand the
implementation and its recipients, as well as for formative
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evaluation. Data sources include: observations of NCM
trainings in Boston, the TA team’s site visit(s) to intervention clinics, and weekly TA team videoconference calls
with the NCMs; bi-monthly to monthly debriefs with the
TA team to review facilitators and barriers from all sites;
review of email communications using a central study
email box for all trial-related communication, site debriefs
with Site PIs and project managers including periodic
“all-site” phone meetings (initially weekly and decreasing
frequency over the trial) and ad hoc or scheduled debriefs
with a single site. These qualitative data are used as part
of formative evaluation to provide feedback at weekly
leadership meetings leading to discussions about whether
refinements or adaptations of the three implementation
strategies are needed.
Measures
Objective 1: implementation outcome—patient days of OUD
medication treatment

The number of patient days of medication treatment
of OUD documented in the EMR in each clinic in the
2 years post-randomization is the primary outcome
(Table 2). To account for varying clinic sizes, the outcome is divided by the number of patients seen in the
clinics during that time period and then multiplied by an
appropriate scaling factor in order to report the results
(e.g., multiplying by 10,000 to calculate the number of

Table 2 Primary, secondary, and other outcomes measured during the 2 years post-randomization based on EHR data,
as entered into clinicaltrials.gov
Outcome measures
Objective 1. Patient-days of OUD medication treatment (primary outcome) Clinic-level number of patient-days of OUD treatment with buprenorphine
and XR-NTX documented in the EHR during the period from randomization until 2 years after, reported per 10,000 PC patients in the clinic in the 2
years post-randomization
Objective 2. Acute care utilization (secondary outcome) Patient-level number of days of acute care utilization during the period from randomization until
2 years after, among patients with an OUD diagnosis documented in the EHR in the 3 years prior to randomization
Other outcome measures of implementation
Newly diagnosed OUD (implementation reach) Clinic-level number of patients with a new International Classification of Disease (ICD) code for OUD
documented in the EHR during the period from randomization until 2 years after who did not have an OUD diagnosis documented in the EHR in
the 3 years prior to randomization, reported per 10,000 patients in the PC clinic in the 2 years post-randomization
Initiationa of OUD treatment (implementation reach) Clinic-level number of patients who initiate: (1) buprenorphine or (2) XR-NTX with an OUD diagnosis as documented in the EHR during the period from randomization until 2 years after, reported per 10,000 PC patients in the clinic in the 2 years
post-randomization
Retention in OUD treatment (implementation fidelity) Clinic-level number of patients initiatinga OUD treatment during the period from randomization
until 2 years after randomization as documented in the EHR, who also receive OUD treatment on 80% of days available after initiation reported per
10,000 PC patients in the clinic in the 2 years post-randomization [34]
Naloxone prescribing (implementation fidelity) Patient-level number of prescriptions of naloxone for overdose management in the period from randomization until 2 years after, among patients with an OUD diagnosis in the 3 years prior to randomization
Other outcome measures of effectiveness
Urgent care or ED use Patient-level number of visits to urgent care or EDs during the period from randomization until 2 years after, among patients with
an OUD diagnosis documented in the EHR in the 3 years prior to randomization
Inpatient days hospitalized Patient-level number of days hospitalized during the period from randomization until 2 years after, among patients with an
OUD diagnosis documented in the EHR in the 3 years prior to randomization
a

Initiation of buprenorphine and XR-NTX in the context of PROUD trial outcome measures refers to an order for OUD medication treatment post-randomization with
no treatment with these medications in the prior 365 days
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patient days of OUD treatment per 10,000 patients),
and reported as patient-years of treatment provided by a
clinic (calculated by simply dividing days of OUD treatment by 365). This measure was selected as the primary
outcome because: it reflects both initiation and retention
and thus both access and quality; it is continuous and
therefore maximizes statistical power in a study with a
small number of clusters; and it can be estimated in the
entire sample of PC patients to avoid identification bias
[32].
Medication treatment for OUD includes buprenorphine formulations that are FDA approved for OUD or
XR-NTX; methadone is not included since data from
methadone opioid treatment programs (OTPs) are not
available in EMRs and most of the health systems do not
have data on methadone OTPs. An OUD diagnosis for
buprenorphine is not required because Phase 1 analyses
revealed OUD diagnoses are sometimes missing, consistent with the literature [7], and an OUD diagnosis is
more likely to be documented for patients in Intervention
compared to Usual PC clinics, so that requiring an OUD
diagnosis could bias findings toward favoring the intervention. Since XR-NTX is also FDA-approved for AUD,
when both OUD and AUD are documented, XR-NTX is
considered OUD treatment if the number of documented
OUD diagnoses are about equal to AUD (i.e. within two).
Medication orders from EMRs are the basis for the primary outcome. This outcome measure was selected
because not all sites had data on medication dispensing from pharmacies or insurance claims for contracted
OUD treatment in their EHRs, and the trial requires an
outcome that is comparable across all sites. However,
pharmacy dispensing data and insurance claims and
other EHR data, when available, are used for secondary
measures.

Additional exploratory and explanatory measures, planned
both a priori or during the trial prior to data cleaning and
locking of the database, are outlined in the final Statistical
Analysis Plan (available from authors).

Objective 2: main effectiveness outcome—days of acute care
utilization

Statistical analysis
Objective 1: main implementation objective (primary aim)

Acute care utilization, a count measure of the number
of days of acute care utilization in the 2 years after randomization, is the secondary outcome. It is the sum total
of visits to urgent care clinics (not same day appointments in PC) and emergency departments (EDs), and
days hospitalized. This outcome was selected because ED
and hospital care are widely available proxy measures for
adverse outcomes of OUD, hypothesized to improve in
patients with OUD who receive timely medication treatment, and less susceptible to documentation biases than
specific diagnoses (e.g., overdose).
Other outcomes

Other pre-specified outcomes for implementation and
effectiveness based on EHR data are shown in Table 2 [33].

Analyses
Qualitative analyses

Implementation-focused formative evaluation [29] is conducted throughout the trial to assess whether the three
implementation strategies—salary for a NCM, TA and
three PC providers obtaining training and DEA waivers for
buprenorphine treatment—needed any refinement. Formative evaluation uses qualitative data on observed barriers
and facilitators from each site, and iterative discussions
among trial leaders, to arrive at any decisions about refinement of implementation strategies.
To provide context for interpretation of quantitative
findings, the Implementation Monitoring Team also identifies barriers and facilitators to implementation using a
rapid coding process [35] as in prior studies [36]. This coding process consists of four steps. First, at the end of the
study the Implementation Monitoring Team members
each identify up to 10 important barriers and facilitators
of implementation for each health system. Second, after
discussion, the Implementation Monitoring Team arrives
at a consensus regarding key barriers and facilitators for
each site. Third, results for each site are shared with stakeholders (the NCM, Site PIs and Site project managers, and
the TA team), for feedback on appropriate representation
of context and revised accordingly. Finally, barriers and
facilitators are categorized into the PRISM’s four domains
described above: (1) intervention; (2) recipients—patients,
clinicians, managers, staff and organizational leaders; (3)
health system and clinic implementation infrastructure;
and (4) external environment [23].

Main analyses are based on intent-to-treat (“per randomization”), and compare PROUD intervention and Usual PC
clinics regarding the clinic-level number of patient-days of
medication treatment of OUD (per 10,000 patients seen)
over the 2 years after randomization. Analyses fit a mixedeffect model to account for correlation of outcomes from
the pair of clinics from the same health care system,

yij = α + β ∗ trtij + γ ∗ zij + θ j + ǫij
where yij is the primary outcome measure for clinic i at
health care system j , trtij is the treatment indicator (for
PROUD intervention versus Usual PC), and zij is the
observed “baseline” value of the outcome defined over
the 2 years prior to randomization. Additionally, θj is the
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random effect for health system j , assumed to be normally distributed with a common variance, and ǫij is the
error term (also assumed to be normally distributed).
To evaluate whether the PROUD intervention increases
EMR-documented OUD treatment, analyses test whether
β significantly exceeds zero using a one-sided hypothesis
test at the 0.05 level. This is appropriate because our primary aim is to test superiority of implementation of the
MA model relative to Usual PC in order to inform health
systems’ decisions as to whether to implement this model
of OUD care.
Given the small number of clusters and the potential
for chance imbalance in covariates, secondary analyses are conducted adjusting for covariates predictive
of OUD medication treatment days during the baseline
period; these are identified using baseline data to select
at most two covariates most strongly associated with
days of OUD medication treatment during the baseline
period (given the limited available degrees of freedom).
Other secondary analyses of the primary (implementation) outcome include: site-specific (descriptive) analyses
comparing PROUD intervention and Usual PC clinics at
each site; “per protocol” analyses (1) restricted to health
systems whose intervention clinic’s NCM treated over
30 patients (indicating successful implementation), or (2)
using a modified definition of the follow-up period over
which the Objective 1 outcome measure is calculated
(e.g., after the NCM began seeing patients to account
for delay in implementation due to NCM hiring and
training). Additional sensitivity analyses are conducted
in which the outcome specifications are varied (e.g.,
using the most complete EHR data available from each
site by including pharmacy dispensing and insurance
claims data from sites where it is available). Descriptive
analyses also evaluate crossover from a Usual PC clinic
pre-randomization to the PROUD intervention clinic
post-randomization in patients with OUD. Analyses of
other pre-specified implementation outcomes (Table 2)
use largely the same general approach as for the primary
outcome. Exploratory outcomes also describe different dimensions of implementation based on the PRISM
model such as adoption (e.g., proportion of PC providers
who prescribe buprenorphine), implementation fidelity
(e.g., use of urine drug tests). Differences between intervention and Usual PC clinics, and any changes in PC staff
attitudes from baseline to after the trial ends will also be
assessed.

intervention and those in Usual PC clinics. The primary
analyses of effectiveness exclude patients newly diagnosed with OUD post-randomization, as these patients
could differ systematically between PROUD intervention and Usual PC clinics, if the MA Model attracts new
patients into PC [18], which could lead to biased estimates of the treatment effect [32]. A mixed-effect Poisson regression model (with log link) is fit at the patient
level to the number of days of acute care utilization.
The model adjusts for the baseline value of the outcome
(count measure of the number of days of acute care utilization) and accounts for clustering of patients within a
clinic by including clinic-specific random intercepts. If
any site randomizes after 2/28/2018, analyses would also
adjust for time from randomization to the end of the trial
(2/29/2020) by including an offset term. The Objective 2
effectiveness hypothesis is evaluated by testing whether
the coefficient of the intervention group assignment
(PROUD versus Usual PC) differs from zero using a twosided test at the 0.05 level with a small-sample correction
method given the small number of clusters in the analysis
[37, 38].
Several secondary effectiveness analyses of the Objective 2 outcome are planned. Examples include adjusting
for additional patient-level variables and expanding the
analytic sample to include patients with newly documented OUD post-randomization. In addition, other
effectiveness outcomes (Table 2) are analyzed using a
similar approach as for the Objective 2 outcome.

Objective 2: main effectiveness objective

Planned observational comparisons
Observational comparisons

Analyses to assess effectiveness evaluate, among individuals who have an OUD diagnosis prior to randomization, whether acute care utilization during follow-up
differs between those in clinics assigned to the PROUD

Differences in PROUD intervention impact on Objective 1
outcome across age, sex and race/ethnicity

Given the importance of understanding how the MA
Model improves care for subpopulations, subgroup analyses are conducted based on: age (< 26 vs. older); sex; race
and ethnicity. Any such comparisons are likely underpowered and must be interpreted with caution. The original Massachusetts studies observed that patients who
were male or Black/African American or Hispanic were
less likely to be retained in PC treatment of OUD with
the MA Model, compared to female and white patients,
respectively [17, 28], but no differences were observed
across age groups. As a result, PROUD investigators
hypothesize that the intervention will result in smaller
increases in OUD medication treatment in patients who
are male or Black/African American or Hispanic, but
hypothesize no differences across age groups.

Several observational comparisons are planned. To evaluate whether PC clinics in the PROUD trial differed from
other PC clinics in the same health systems, recruited and
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non-recruited PC clinics are compared in the five health
systems able to provide data on four non-recruited (nonrandomized) Usual PC clinics. Specifically, patients in the
10 recruited clinics are compared to 20 non-recruited PC
clinics during the pre-randomization period in these five
health systems (Fig. 1). Implementation and effectiveness outcomes in the second year after randomization are
also compared in observational analyses between the six
intervention clinics and the four exemplar programs for
OUD, described above.
Economic analyses

The PROUD trial is providing data for an ancillary economic analysis of the health system costs with the following outcomes: (a) the cost of implementing the MA
Model; (b) the mean per-person daily cost of delivering
the MA Model on an ongoing basis; (c) the differences
in the mean per-person costs associated with PC, behavioral healthcare, ED, and inpatient services between
the study arms over the post-randomization observation period; (d) the difference in the average total cost
of healthcare service utilization between the study arms
over the post-randomization observation period; and (e)
the difference between (d) and (b), which represents the
incremental net benefit of the PROUD intervention. A
description of the protocol for this ancillary study will be
forthcoming in a separate publication.
Power
Objective 1 (primary aim)

Power calculations for Objective 1 assessed whether there
is sufficient power (> 80%) to detect a fivefold increase in
the number of patient days of OUD medication treatment associated with the PROUD intervention as compared to Usual PC. There is no agreed upon benchmark
for high quality OUD treatment, and an increase of this
magnitude, which could reflect a fivefold increase in the
number of patients who access and/or are retained in
treatment, was felt to be clinically-relevant and a substantial enough increase to convince policy-makers.
Simulations, using PROUD phase 1 data, were conducted
to calculate power under the planned analytic approach,
as described above (mixed-effect regression model that
adjusts for the baseline value of the outcome), with a onesided test with a type 1 error rate of 0.05. Parameter values for the simulation were estimated using Phase 1 data
on the 12 clinics recruited into the PROUD trial (two
clinics from each health system). Details on the data-generating model for the simulation along with the specific
parameter values are in the study Statistical Analysis Plan
(available from authors). Based on these simulations, the
PROUD trial is estimated to have at least 80% power to
detect a 30% increase in the number of OUD-treated
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days per patient seen in PC. Because 30% is far smaller
than the fivefold (400%) clinically- or policy-meaningful
increase, the study is sufficiently powered with two clinics in each of six health care systems to detect the targeted fivefold increase in the primary outcome measure.
Objective 2 (secondary aim)

Power calculations for Objective 2 used simulations to
calculate the power to detect a reduction in acute care
utilization among patients with an OUD diagnosis prerandomization, comparing PROUD intervention versus
Usual PC clinics, under a range of assumed values of the
effect size, as well as a range of assumed values for the
proportion of patients with OUD treated by the PROUD
NCM. Outcome data on acute care utilization for simulations were generated using a Poisson mixed-effect model
with sample size and parameters estimated using Phase
1 data for the 12 clinics recruited into the PROUD trial.
These simulations assumed that among patients with
OUD in the PROUD intervention clinic, those who visit
the PROUD NCM and receive sustained treatment with
buprenorphine or XR-NTX would have 10–20% of the
rate of acute care utilization (i.e., a relative rate RRtreat of
0.1–0.20) as patients with OUD who are not treated for
OUD by the PROUD NCM, since sustained treatment for
OUD is hypothesized to markedly reduce acute care utilization [39]. To each simulated dataset a Poisson mixedeffect model was fit applying the between-within (BW)
DF corrected F test [37] with a (2-sided) type-1 error rate
of 0.05. Under effect size of RRtreat of 0.1–0.2 the PROUD
trial has over 80% power if at least 39–44% of patients
with OUD in the PROUD intervention arm pre-randomization are treated for OUD.
Trial status

The PROUD Trial intervention ends 2/29/2020. Final
quantitative and qualitative data collection occurs
March–September 2020. Main results are expected
by 8/2021. Results will be published in peer reviewed
journals.

Discussion
Despite the availability of first-line medication treatment
for OUD that can be provided in PC, many practices
do not offer such treatment. The PROUD trial seeks to
address this gap by implementing a promising model, the
MA model, into PC to engage patients in OUD treatment
in medical settings. The MA Model is a collaborative
care model designed to support treatment of OUD in PC
practices by providing nurse support for all elements of
care, except OUD diagnosis and medication prescribing
[17, 18, 28]. This model of shared-care between a PC provider and NCM was also designed to address knowledge
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gaps, lack of time, need for clinic support, and stigma,
which are common barriers to treatment of OUD in PC
[11, 12, 15]. Promising reports [17–19] suggest that the
MA Model allows a nurse to develop deep expertise in
OUD treatment, supported by national experts, as a way
to improve access, overcome stigma and support the
development of local PC expertise in OUD treatment
[17–19]. The model also allows PC providers to treat
many more patients with OUD than they could alone—
up to 100 per NCM [18]. The PROUD trial is designed to
provide information for clinical leaders and policy makers regarding benefits and costs of the MA Model by testing the model in real-world PC settings in diverse health
systems. The trial relies on health systems to implement
the model and uses secondary data to identify the study
samples and evaluate implementation and effectiveness
outcomes. As a result, all PC patients who visited the
randomized clinics over the study period are included in
primary analyses. The PROUD trial can provide a roadmap for other health systems searching for a practical
care model for OUD treatment in PC.
Limitations and strengths

In this pragmatic trial that relies on EHR data for defining the primary and secondary outcomes, the data can be
a limitation to the trial’s internal validity. For the primary
outcome (days of medication treatment for OUD), orders
for buprenorphine or XR-NTX in the EMR could be
written and never dispensed or ingested (for oral medications), and patients could obtain OUD treatment outside
the participating health systems - including methadone
from opioid treatment programs—that may not be documented in the EHR [40]. There is no way to determine
whether services were not provided or whether the data
are missing, and external OUD treatment data are not
included in the primary outcome measure because they
are unavailable at most sites. However, randomization
is stratified within health system and the participating
health systems provide the vast majority of care for the
populations they serve; therefore, limitations in outcome
data should be similar in both arms within a site. Limitations of data sources are also addressed with sensitivity analyses which vary the specification of the outcome
(e.g., to include dispensing of medications, insurance
claims, and methadone data at sites where available) to
estimate whether this meaningfully changes the main
results. Incomplete ascertainment of acute care utilization could also under-estimate or bias results regarding
effectiveness (Objective 2) as only two participating systems are health insurance plans with claims data. However, analyses of acute care utilization among patients
with OUD are adjusted for patients’ pre-randomization
acute care utilization, and stratified randomization
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ensures that systematic differences in ascertainment
between health systems are balanced across intervention groups. Another limitation is that only some adverse
health effects of OUD lead to urgent, emergency, or hospital care, and although other outcomes are evaluated,
many adverse outcomes of OUD cannot be ascertained
from EHRs. Further, many PC patients with OUD do not
have a documented OUD diagnosis and are therefore
excluded from Objective 2 analyses, and others may leave
or obtain care outside the health system, which can only
be ascertained for the two systems with health insurance
plans and claims data. However, sensitivity analyses are
planned that include patients with documented OUD
post-randomization or require PC visits post-randomization (as a proxy for continued enrollment). In addition, if
the trial finds that the MA Model meaningfully increases
OUD treatment, a future planned ancillary study will
obtain population-based death data from the National
Death Index to evaluate the intervention’s impact on
death among patients with documented OUD.
Limitations to external validity relate to the cost of the
nurse, which is not borne by the health systems, and the
fact that sites recruited are a select group of clinics with a
leader and/or clinicians willing to participate in the trial.
The MA Model’s requirement for a large upfront investment in a full-time NCM and regional shortages of nurses
might limit generalizability. However, additional observational comparisons evaluate outcomes in the PROUD
intervention clinics compared to potentially more generalizable “exemplar” models of OUD care already in
place and compare recruited and randomized PC clinics
to non-recruited PC clinics before randomization. Prior
research suggests that some PC providers are not willing
to prescribe, and models that utilize non-physicians may
be needed [4]. Finally, a limitation of using “usual care”
as a comparison is that its characteristics must be clearly
described at baseline and changes over the course of a
trial must be clearly ascertained and described [41]. To
understand usual care provided in control clinics (and its
generalizability), the Implementation Monitoring Team
conducts robust assessment at baseline and monitoring
throughout the study, with qualitative and quantitative
data collected by each site’s PI and project manager, while
avoiding contact between researchers and sites.
At the same time, the PROUD trial has important
strengths related to its design, sample, and innovative
measures allowing evaluation of the MA model in diverse
naturalistic settings. The pragmatic design of the trial
allows the study of a sample of patients with OUD seen
in PC who seldom seek OUD treatment or enroll in trials. Further, the design allows evaluation of treatment
engagement and acute care outcomes over a 2-year follow-up period. Each system agreed to implement the MA
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Model in one randomly selected PC clinic and to provide
data from 3 years before and 2 years after randomization.
The trial obtains adequate statistical power for a trial
with 12 clinics by using a novel primary outcome measure of patient-days of medication treatment for OUD
per 10,000 PC patients seen, which reflects both access
and retention. The trial design also allows evaluation of
the extent to which the MA Model attracts new patients
into PC for OUD treatment or leads to newly recognized OUD in the intervention clinics. An innovative
Implementation Monitoring Team assesses usual care at
baseline and monitors usual care and intervention implementation over time, identifying barriers and facilitators
in each system, which allows interpretation of variation
in outcomes across sites. Further, the trial includes geographically diverse health systems that serve racially and
ethnically diverse populations and have varying organization of health care delivery and financing, including two
safety net systems, one academic system, one regional
healthcare delivery system, and two systems that integrate health insurance with care delivery.

Conclusion
The PROUD trial is an innovative pragmatic trial that is
evaluating the ability of the MA Model to improve access
to and retention in OUD treatment in PC clinics in six
diverse health systems. Results will provide critical evidence to help health system leaders evaluate whether
investing upfront in a full-time NCM for OUD treatment
increases OUD treatment in PC and decreases the need
for acute care.
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